Sorted Akt2T309A-OE CTLs exhibited impaired antitumor activity, as evidenced by sustained bioluminescence signals and a lack of tumor regression, in contrast to the robust tumor clearance observed with Akt2-OE CTLs (figure 3F, online supplemental figure S7). Here, AKT2 is linked to neoplasm.